MedPath
HSA Approval

TONIN COUGH SYRUP S

SIN09666P

TONIN COUGH SYRUP S

TONIN COUGH SYRUP S

March 7, 1998

SATO PHARMACEUTICAL (SINGAPORE) PTE LTD

SATO PHARMACEUTICAL (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantSATO PHARMACEUTICAL (SINGAPORE) PTE LTD
Licence HolderSATO PHARMACEUTICAL (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

R05FA02

opium derivatives and expectorants

Manufacturer Information

SATO PHARMACEUTICAL (SINGAPORE) PTE LTD

SATO PHARMACEUTICAL CO LTD

Active Ingredients

NOSCAPINE HCl

60 mg/30 ml

Noscapine

GUAIFENESIN

300 mg/30 ml

Guaifenesin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TONIN COUGH SYRUP S - HSA Approval | MedPath